Home » JOHNSON & JOHNSON INITIATED WITH 'BUY'
JOHNSON & JOHNSON INITIATED WITH 'BUY'
Analysts at UBS initiate coverage of Johnson & Johnson with a "buy"
rating. The target price is set to $80.
Newratings
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May